Bolt Biotherapeutics grants 10,000 options to COO

Bolt Biotherapeutics, Inc. reported that its Chief Operating Officer, Yonehiro Grant, received an employee stock option grant.

Rhea-AI Filing Summary

Bolt Biotherapeutics, Inc. reported that its Chief Operating Officer, Yonehiro Grant, received an employee stock option grant. On January 28, 2026, Grant was awarded options to purchase 10,000 shares of Bolt common stock at an exercise price of $6.71 per share, expiring January 27, 2036.

The options vest over time, so long as Grant continues providing services to Bolt. Starting from January 1, 2026, 1/36 of the options vest after each completed month of continuous service, until all 10,000 options are fully vested.

Insider Trade Summary

Grant/Award: 10,000 shares

Grant/Award 1 txn

Insider Yonehiro Grant

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	10,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 10,000 contracts (Direct)

Footnotes (1)

1. F1. For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Bolt Biotherapeutics (BOLT) disclose in this Form 4 filing?

Bolt Biotherapeutics disclosed an option grant to its Chief Operating Officer, Yonehiro Grant. The filing reports 10,000 employee stock options, detailing the grant date, exercise price, expiration date, and a monthly vesting schedule contingent on continued service to the company.

How many stock options were granted to the Bolt Biotherapeutics (BOLT) COO?

The Chief Operating Officer, Yonehiro Grant, was granted options on 10,000 shares of Bolt common stock. These options are reported as directly owned derivative securities and represent the full amount beneficially owned following the reported transaction in the Form 4.

What is the exercise price of the COO’s stock options at Bolt Biotherapeutics (BOLT)?

The employee stock options granted to Yonehiro Grant carry an exercise price of $6.71 per share. This is the price at which she may buy Bolt common stock upon exercising the options within the option’s stated term, subject to vesting conditions.

When do the Bolt Biotherapeutics (BOLT) COO stock options vest?

The options vest monthly, conditioned on continued service. Starting January 1, 2026, 1/36 of the 10,000 options vest after each completed month of continuous service, creating a three-year vesting schedule linked directly to ongoing employment with Bolt Biotherapeutics.

What is the expiration date of the COO’s options at Bolt Biotherapeutics (BOLT)?

The employee stock options granted to Chief Operating Officer Yonehiro Grant expire on January 27, 2036. After this expiration date, any unexercised portion of the 10,000 options will no longer be exercisable under the terms reported in the Form 4.

Is the Bolt Biotherapeutics (BOLT) COO’s option ownership direct or indirect?

The Form 4 reports the 10,000 employee stock options as directly owned by Yonehiro Grant. The ownership form is listed as “D” for direct, with no indication of indirect ownership through another entity or separate beneficial owner.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 04:32 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yonehiro Grant

(Last) (First) (Middle)

C/O BOLT BIOTHERAPEUTICS, INC.

900 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Bolt Biotherapeutics, Inc. [ BOLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$6.71	01/28/2026		A		10,000		(1)	01/27/2036	Common Stock	10,000	$0	10,000	D

Explanation of Responses:

1. For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2026.

	/s/ William P. Quinn, Attorney-in-Fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.